drugset / Trial / NCT02210182
A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to investigate on the Hepatic Uptake, Pharmacokinetics, Safety and Tolerance of a New Oral Pentamidine Formulation in Hepatocellular Carcinoma Subjects Undergoing Thermal Ablation
Timeline
- Start
- 2014-08
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pentamidine | Unknown | 300 mg | Oral |
| Subject | Pentamidine | Unknown | 600 mg | Oral |
| Subject | Pentamidine | Unknown | 900 mg | Oral |
| Subject | Pentamidine | Unknown | 1200 mg | Oral |